Enzalutamide
Phase 2Withdrawn 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Castration-Resistant Prostate Cancer
Conditions
Metastatic Castration-Resistant Prostate Cancer
Trial Timeline
Aug 1, 2012 → Oct 1, 2014
NCT ID
NCT01663415About Enzalutamide
Enzalutamide is a phase 2 stage product being developed by Astellas Pharma for Metastatic Castration-Resistant Prostate Cancer. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT01663415. Target conditions include Metastatic Castration-Resistant Prostate Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05404139 | Phase 2 | Recruiting |
| NCT02749903 | Phase 2 | Active |
| NCT02799745 | Phase 2 | Completed |
| NCT02750358 | Phase 2 | Active |
| NCT02605863 | Phase 2 | Terminated |
| NCT02384382 | Phase 2 | Completed |
| NCT02441517 | Approved | Terminated |
| NCT02507570 | Phase 2 | Completed |
| NCT02495974 | Pre-clinical | Completed |
| NCT02203695 | Phase 2 | Completed |
| NCT02288936 | Phase 2 | Completed |
| NCT02669771 | Pre-clinical | Completed |
| NCT02124668 | Phase 2 | Completed |
| NCT03297385 | Phase 2 | Completed |
| NCT02116582 | Approved | Completed |
| NCT02099864 | Phase 2 | Completed |
| NCT01977651 | Approved | Completed |
| NCT02138162 | Phase 1 | Completed |
| NCT01889238 | Phase 2 | Completed |
| NCT01663415 | Phase 2 | Withdrawn |
Competing Products
20 competing products in Metastatic Castration-Resistant Prostate Cancer